Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(26 sites)

Finland

Helsinki University Hospital, Helsinki

Kuopio University Hospital, Kuopio

Tampere University Hospital, Tampere

Turku University Hospital, Turku

Norway

Ålesund Hospital, Ålesund

Haukeland University Hospital, Bergen

Sorlandet Hospital, Kristiansand

Akershus University Hospital, Oslo

Oslo University Hospital, Oslo

Stavanger University Hospital, Stavanger

North Norway University Hospital, Tromsø

Trondheim University Hospital, Trondheim

Sweden

Eskilstuna Hospital, Eskilstuna

Falu Hospital, Falun

Gävle Hospital, Gävle

Sahlgrenska University Hospital, Gothenburg

Ryhov Hospital, Jönköping

Kalmar Hospital, Kalmar

Karlstad Hospital, Karlstad

Linköping University Hospital, Linköping

Skåne University Hospital, Lund

Örebro University Hospital, Örebro

Karolinska University Hospital, Stockholm

Sundsvall Hospital, Sundsvall

Växjö Hospital, Vaxjo

Västmanland Hospital, Västerås